Amgen Inc.

Kristin L Andrews

Mark Henry Norman

Jennifer Rebecca Allen

Nobuko Nishimura

Shon Booker

Kevin Chao Yang

Robert Michael Rzasa

Longbin Liu

Nuria A Tamayo

Alexander J Pickrell

Yunxin Y Bo

Jian Jeffrey Chen

Ning Chen

Thomas T Nguyen

Qingyian Liu

Bin Wu

Anthony B Reed

Liping H Pettus

Wenge Zhong

Victor J Cee

Michael J Frohn

Albert Kudzovi Amegadzie

Brian Alan Lanman

Ryan Paul Wurz

Laurie B Schenkel

Aaron C Siegmund

Chester Chenguang Yuan

Paul E Harrington

James A Brown

Wenyuan Qian

Shannon Rumfelt

Adrian Leonard Smith

Fang-Tsao Hong

Bradley J Herberich

Noel D'Angelo

Seifu Tadesse

Holly L Deak

Essa Hu Harrington

Marian C Bryan

Claire L M Jackson

Hongyu Liao

Kathleen Panter

Adrian L Smith

Noel D'angelo

Claire L Jackson

Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

Heterobicyclic compounds

Aryl- and heteroaryl-nitrogen heterocyclic compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein m, p, q, R, R, R, X, X, X, Yand Yare defined herein; and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.

Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.

Inhibitors of PI3 kinase and/or mTOR

The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein Q, X, X, Rand Z are as defined herein. 

Inhibitors of PI3 kinase

Growing community of inventors

Thousand Oaks, CA, United States of America

Kristin L Andrews